Using multiple risk models with preventive interventions

Statistics in Medicine

Volumn 31, Issue 23, 2012, Pages 2687-2696

  Gail, Mitchell H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Absolute risk models; Breast cancer; Disease prevention; Modeling multiple risks; Risk versus benefit; Risk based prevention strategy

Indexed keywords

ACCURACY; ARTICLE; BREAST CANCER; CANCER RISK; CONTROL STRATEGY; DISCRIMINANT ANALYSIS; MATHEMATICAL MODEL; MEDICAL DECISION MAKING; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STROKE;

BREAST NEOPLASMS; FEMALE; HUMANS; MODELS, STATISTICAL; NUMERICAL ANALYSIS, COMPUTER-ASSISTED; RISK ASSESSMENT; SELECTIVE ESTROGEN RECEPTOR MODULATORS; STROKE; TAMOXIFEN;

EID: 84866440065     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.5443     Document Type: Article

References (15)

1. Rose GA.The Strategy of Preventive Medicine. Oxford University Press: Oxford, 1992.
2. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N.Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. Journal of the National Cancer Institute 1998; 90:1371-1388.
3. Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, Vogel V.Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. Journal of the National Cancer Institute 1999; 91:1829-1846.
4. Gail MH.Personalized estimates of breast cancer risk in clinical practice and public health. Statistics in Medicine 2011; 30:1090-1104.
5. Gail MH, Pfeiffer RM.On criteria for evaluating models of absolute risk. Biostatistics 2005; 6:227-239.
6. Pfeiffer RM, Gail MH.Two criteria for evaluating risk prediction models. Biometrics 2011; 67:1057-1065.
7. Pharoah PDP, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BAJ.Polygenic susceptibility to breast cancer and implications for prevention. Nature Genetics 2002; 31:33-36.
8. Baker SG, Cook NR, Vickers A, Kramer BS.Using relative utility curves to evaluate risk prediction. Journal of the Royal Statistical Society Series A 2009; 172:729-748.
9. Gail MH.Value of adding single-nucleotide polymorphism genotypes to a breast cancer risk model. Journal of the National Cancer Institute 2009; 101:959-963.
10. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, Mulvihill JJ.Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. Journal of the National Cancer Institute 1989; 81:1879-1886.
11. Wolf PA, Dagostino RB, Belanger AJ, Kannel WB.Probability of stroke - a risk profile from the Framingham Study. Stroke 1991; 22:312-318.
12. Chen JB, Pee D, Ayyagari R, Graubard B, Schairer C, Byrne C, Benichou J, Gail MH.Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. Journal of the National Cancer Institute 2006; 98:1215-1226.
13. Rosner BA, Colditz GA, Webb PM, Hankinson SE.Mathematical models of ovarian cancer incidence. Epidemiology 2005; 16:508-515.
14. Gail MH.Applying the Lorenz curve to disease risk to optimize health benefits under cost constraints. Statistics and Its Interface 2009; 2:117-121.
15. Freedman L, Anderson G, Kipnis V, Prentice R, Wang CY, Rossouw J, Wittes J, DeMets D.Approaches to monitoring the results of long-term disease prevention trials: Examples from the women's health initiative. Controlled Clinical Trials 1996; 17:509-525.